Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide

Protagonist Therapeutics plans to conduct a two-year extension study, PTG-300-21, to evaluate the long-term effects of rusfertide in patients with polycythemia vera (PV). The decision was based on positive results from the REVIVE study of rusfertide in PV, which showed sustained and durable hematocrit control under 45% in patients who remained largely phlebotomy-free. Nearly 70% of subjects rece..